Qualigen Therapeutics Return on Equity

Qualigen Therapeutics (QLGN) currently reports a ROE of -448.16%. That is below the Healthcare sector average of -100.59%. Use the charts on this page to explore Qualigen Therapeutics's ROE history and peer comparisons.

Qualigen Therapeutics's ROE of -448.16% is lower than the Healthcare sector average of -100.59%. That is roughly 345.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Qualigen Therapeutics's current -448.16% should be judged against Healthcare norms (sector average: -100.59%) and against QLGN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -448.16%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -100.59%. From there, open related valuation or income-statement pages for Qualigen Therapeutics, and consider following QLGN for alerts when major investors trade the stock.

Qualigen Therapeutics is classified in the Healthcare sector. On ROE, it currently shows -448.16% versus a sector average near -100.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing QLGN with unrelated industries.